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The presence of polyvascular disease, defined as atherosclerosis involving more than one distinct 
vascular territory, is a strong, independent predictor of cardiovascular events.1-4 In the LEADER 
trial,5 the human glucagon-like peptide 1 analog liraglutide reduced cardiovascular events in 
patients with type 2 diabetes (T2D) at high cardiovascular risk. In this post hoc analysis of 
LEADER, we evaluated the effects of liraglutide stratified by number of atherosclerotic vascular 
territories (coronary, cerebrovascular, and/or peripheral) 
Data and analytic methods supporting this study’s findings are available from the 
corresponding author upon reasonable request. LEADER (ClinicalTrials.gov NCT01179048) was 
a randomized trial of liraglutide (1.8 mg or maximum tolerated dose) versus placebo in 9340 
patients with T2D and high cardiovascular risk (median follow-up=3.8 years).5 The primary 
outcome was a composite of cardiovascular death, non-fatal myocardial infarction (MI), or non-
fatal stroke (major adverse cardiovascular events, MACE). The key secondary expanded outcome 
(expanded MACE) also included hospitalization for unstable angina, coronary revascularization, 
or hospitalization for heart failure. 
The ethics committee or institutional review board at each participating center approved 
the trial protocol. Patients provided informed consent. Cardiovascular outcomes were 
prospectively adjudicated by an independent, blinded event adjudication committee. 
Atherosclerotic vascular territories included coronary (MI, ≥50% coronary artery stenosis, 
percutaneous coronary intervention or coronary artery bypass graft surgery, angina pectoris, or 
asymptomatic ischemia), cerebrovascular (stroke, transient ischemic attack, ≥50% intracranial or 
carotid artery stenosis) and peripheral arteries (≥50% peripheral artery stenosis). Information was 
extracted from patients’ baseline medical history. Risk groups were determined by number of 
  
vascular territories involved: polyvascular disease as two or more, single vascular disease as one, 
and a group with no documented atherosclerotic cardiovascular disease (ASCVD). 
 The hazard ratios (HRs) comparing risk groups were calculated using a Cox proportional 
hazards model with treatment and risk group as factors. The treatment effect of liraglutide versus 
placebo within risk groups was estimated using Cox proportional hazards regression model with 
treatment, risk group, and the interaction of both as factors.  
In LEADER, 6775 patients (72.5%) had documented ASCVD. In patients with ASCVD, 
1536 (23%) had a baseline history of polyvascular disease, and 5239 (77%) had single vascular 
disease. For the total population, the distribution of vascular territory involvement is shown in 
Figure, A. Briefly, 5364 patients (57.4%) had a history of coronary artery disease, 1968 (21.1%) 
had cerebrovascular disease, 1184 (12.7%) had peripheral artery disease, and 2665 (27.5%) had 
no documented ASCVD. At baseline, in patients with polyvascular disease versus single vascular 
disease, mean age±standard deviation was higher (65.1±7.7 versus 63.5±7.3 years), more patients 
were male (68.8 versus 67.9%), current or previous smokers (67.1 versus 60.1%), had an estimated 
glomerular filtration rate <60 ml/min/1.73m2 (27.1 versus 19.0%), had history of heart failure (26.4 
versus 16.5%), MI (47.2 versus 39.7 %), stroke (33.5 versus 10.0%), or peripheral artery disease 
(47.1 versus 8.5%), and there was a higher frequency of cardiovascular medication use (95.6 versus 
92.7% for antihypertensive therapy, 83.8 versus 79.2% for lipid-lowering therapy, and 79.7 versus 
75.7 % for antiplatelet therapy). Baseline hemoglobin A1c was similar between groups. 
 Patients with polyvascular disease had a higher risk of cardiovascular outcomes than those 
with single vascular disease (MACE: HR 1.52, 95% confidence interval [CI] 1.33–1.73; expanded 
MACE: HR 1.45, 95% 1.31–1.62, cardiovascular death: HR 1.41, 95% CI 1.13–1.75) (Figure, B, 
C).  
  
Liraglutide reduced MACE consistently in patients with polyvascular (HR 0.82, 95% CI 
0.66–1.02) and with single vascular disease (HR 0.82, 95% CI 0.71–0.95). Results were similar 
for expanded MACE and cardiovascular death (Figure, C). The risk reduction in MACE and 
expanded MACE was similar to that of the total trial population in LEADER (Figure, C).5 The 
corresponding data for non-fatal MI and stroke are displayed in Figure, C.  
In patients without ASCVD at baseline, the HR for liraglutide versus placebo for MACE 
was 1.08 (95% CI 0.84–1.38), with similar results for expanded MACE and cardiovascular death 
(Figure, C). However, no significant interaction was found among risk groups, except for expanded 
MACE (pinteraction=0.03), which could be a chance finding since no adjustment for multiple testing 
was performed or may suggest a difference in treatment effects across risk groups, driven by the 
group without ASCVD (Figure, C). The reason for a neutral response in patients without ASCVD 
could be that the baseline risk was lower, and to establish any potential effect might require a 
longer treatment period or larger sample size. Nevertheless, patients with T2D benefit from 
liraglutide treatment regarding glycemic control, potential weight reductions, and better blood 
pressure control. 
 In patients with T2D and documented ASCVD, the presence of polyvascular disease was 
associated with greater cardiovascular risk versus those with single vascular disease. Liraglutide 
appeared consistently to reduce major cardiovascular outcomes in both patients with polyvascular 
and single vascular disease. 
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Figure: Analysis of LEADER data stratified by number of atherosclerotic vascular 
territories (no ASCVD: no documented evidence of atherosclerotic disease in any of three 
vascular territories [coronary artery, cerebrovascular or peripheral artery]; single vascular disease: 
atherosclerotic disease in one of the three vascular territories; polyvascular disease: atherosclerotic 
disease in two or more of the specified vascular territories). Panel A, Venn diagram of number 
(%) of patients according to number of vascular territories involved at baseline. Panel B, Kaplan-
Meier estimates of time to first primary MACE (composite of cardiovascular death, non-fatal 
myocardial infarction, or non-fatal stroke): (i), and expanded MACE (composite of the primary, 
with hospitalization for unstable angina, coronary revascularization, or hospitalization for heart 
failure also included) and (ii), based upon number of number of vascular territories involved at 
baseline. Panel C, cardiovascular outcomes by number of vascular territories involved. Hazard 
ratios and 95% CIs are based on Cox regression analyses. Interaction p-value is for test of 
homogeneity of treatment group difference among all 3 subgroups (no ASCVD, single vascular 
disease, and polyvascular disease) with no adjustment for multiple tests. ASCVD, atherosclerotic 
cardiovascular disease; CAD, coronary artery disease; CD, cerebrovascular disease; CI, 
confidence interval; MACE, major adverse cardiovascular event; PAD, peripheral artery disease. 
  
  
 
 
 
